This site is intended for healthcare professionals

Novartis reports late-breaking data from phase III COMBI-i trial of spartalizumab (PDR 001) with Tafinlar and Mekinist in advanced melanoma.

Read time: 2 mins
Last updated:28th Jun 2021
Published:20th Sep 2020
Condition: Metastatic Melanoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest